GlassScriptPhysician profile
Shruti Shah
NPI 1114158755
$4,772.51
in general payments reported to CMS, 2019-2025
33 companies · $607 in 2025
The $607 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $583 · 2020: $87.62 · 2021: $739 · 2022: $851 · 2023: $516 · 2024: $1,389 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,989 · Travel and Lodging: $516 · Education: $6.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,988.74 |
| Travel and Lodging | $516.34 |
| Education | $6.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $971.95 | 2021-2025 | Sprint Pns System |
| Si-Bone, INC. | $725.59 | 2019-2023 | |
| Curonix LLC | $705.50 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Boston Scientific Corporation | $360.67 | 2019-2025 | Watchman Flx, General - Pain Management, Wavewriter Alpha Prime 16 |
| Medtronic, INC. | $318.04 | 2022-2024 | Intellis Adaptivestim |
| Scilex Pharmaceuticals INC. | $256.70 | 2021-2024 | Ztlido |
| Kowa Pharmaceuticals America, INC. | $198.75 | 2022-2023 | Seglentis, Livalo |
| Biotronik Nro, INC. | $191.16 | 2024-2025 | Prospera |
| Nevro Corp. | $146.93 | 2019-2024 | Senza |
| Averitas Pharma INC. | $108.17 | 2024-2025 | Qutenza |
| Medtronic USA, INC. | $100.46 | 2019-2020 | |
| Vertos Medical, INC. | $68.86 | 2021 | |
| Nuvasive, INC. | $66.79 | 2019 | |
| Bioventus LLC | $64.66 | 2021-2025 | Durolane, Supartz Fx Sodium Hyaluronate |
| Nalu Medical, INC. | $51.62 | 2024 | Nalu Neurostimulation System |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $49.43 | 2024-2025 | Orthovisc, Monovisc |
| Abbott Laboratories | $48.26 | 2024 | Octrode, Eterna, Proclaim |
| Novo Nordisk INC | $40.59 | 2019-2022 | |
| Azurity Pharmaceuticals, INC. | $31.40 | 2025 | Horizant |
| Globus Medical, INC. | $27.21 | 2025 | Senza |
| Merck Sharp & Dohme LLC | $26.82 | 2019-2021 | |
| Fidia Pharma USA INC. | $26.67 | 2025 | Hymovis, Triluron |
| Almatica Pharma LLC | $26.57 | 2021 | |
| Phadia US INC. | $20.22 | 2020 | |
| Saluda Medical Americas, INC. | $18.20 | 2024 | Evoke |
| Tonix Medicines, INC. | $17.12 | 2025 | Tonmya |
| Lucid Diagnostics INC. | $16.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.00 | 2021 | |
| Astellas Pharma US INC | $14.97 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.93 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.74 | 2022 | |
| Amgen INC. | $14.66 | 2021 | |
| Ibsa Pharma INC. | $13.87 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shruti Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.